To evaluate the short term effects of LACRISERT®. upon fluorescein corneal staining, tear osmolarity and surface topography in human subjects with dry eye disease.

Start Date01 Nov 2016

Sponsor / Collaborator

Virginia Eye Consultants, Inc.

EUCTR2004-001054-84-GB / Not yet recruitingIIT

A comparison of the efficacy of dietary hydroxypropylcellulose and questran as therapeutic agents in bile acid induced diarrhoea - Hydroxypropylcellulose and questran compared

Start Date16 Feb 2005

Sponsor / Collaborator-

100 Clinical Results associated with Hydroxypropyl Cellulose

100 Translational Medicine associated with Hydroxypropyl Cellulose

100 Patents (Medical) associated with Hydroxypropyl Cellulose

239

Literatures (Medical) associated with Hydroxypropyl Cellulose

01 Dec 2024·Advanced Science

Hydroxypropyl Cellulose‐Based Meter‐Long Structurally Colored Fibers for Advanced Fabrics

Article

Author: Qin, Qinan ; Xu, Yan

Abstract:

Structurally colored fibers are attractive alternatives to chemically colored fibers due to their rich optical properties, color stability, and environmental friendliness. However, the fabrication of structurally colored fibers using cost‐effective raw materials with the possibility to scale up remains challenging. Here, a simple and scalable approach is developed to fabricate continuous meter‐long structurally colored fibers exhibiting brilliant structural colors across the visible spectrum and helix orientation‐dependent polarization states. The fibers are fabricated by extrusion of concentrated aqueous solutions of chemically crosslinked hydroxypropyl cellulose (HPC). The wavelengths and polarization states can be tuned by solution concentration, relaxation time, and collector's surface energy. The HPC‐based structurally colored fibers display excellent optical stability to mechanical straining, repeated drying/water impregnation, and prolonged heating at 150 °C. It is demonstrated that the HPC‐based structurally colored fibers can be woven into structurally colored fabrics with wavelength‐ and polarization‐coded optical patterns. The current work presents a strategy to tune the chiral nematic order, which constitutes an important step toward mass production of structurally colored fibers with stable and rich optical properties using easily available raw materials.

01 Nov 2024·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Eco-friendly and flexible polysaccharide-based packaging films for fruit preservation

Article

Author: Meng, Yahui ; Long, Zhu ; Dong, Cuihua ; He, Zhibin ; Zhao, Huifang

Food safety and wastage caused by fruit deterioration is a serious global problem. Effective packaging systems for extending the freshness period of fruit play a key role in food safety. In this work, we constructed an eco-friendly and flexible polysaccharide-based packaging film based on hydroxypropyl guar (HPG), cellulose nanocrystals (CNCs), deep eutectic solvents (DES) and anthocyanin (Anth). DES could endow polysaccharide films with multiple hydrogen bond numbers and good stability. Hydroxypropyl guar/cellulose nanocrystals/anthocyanin with 0.2 g deep eutectic solvents (HCA-DES_0.2) had good tensile properties, oxygen barrier properties (3.01 cm³/m²·day·Pa), water resistance (WCA 111.97°), antibacterial (CFU ˂ 10³), and transparency (55.4 %). The preservation tests of grape and blueberry showed that the shelf life of these two fruits was 12-20 days, and the polysaccharide film had great application potential in fruit preservation.

01 Sep 2024·OPTOMETRY AND VISION SCIENCE

Changes in corneal epithelial irregularity following treatment with artificial tears

Article

Author: Showyin, Jared ; Tan, Jacqueline ; Jia, Tianni ; Stapleton, Fiona ; Chidi-Egboka, Ngozi

Significance:

Dry eye sufferers have a highly irregular corneal epithelial surface compared with those without dry eye. This study demonstrated that corneal epithelial thickness irregularity can be significantly reduced after as little as 48 hours following treatment with regular use of topical ocular lubricants.

Purpose:

This study aimed to compare changes in corneal epithelial thickness irregularity factor (EIF) and ocular symptoms in a population with symptoms of dry eye before and up to 4 weeks after treatment with two commercially available lubricating eye drops versus saline.

Methods:

We conducted a prospective single-center, investigator-masked, randomized, parallel-group dispensing study. Participants with moderate to severe symptoms of dry eye (Ocular Surface Disease Index score >23 at baseline) were enrolled and randomly assigned to receive either 0.15% hyaluronic acid + hydroxypropyl guar, 0.2% hyaluronic acid, or saline (16 in each group). Corneal epithelial thickness measurements were obtained along vertical and horizontal CASIA SS-1000 Optical Coherence Tomography scans at baseline and after 48 hours, 2 weeks, and 4 weeks. The Ocular Surface Disease Index questionnaire was administered at baseline, 2 weeks, and 4 weeks.

Results:

Forty-eight participants (male-to-female ratio, 17:31) completed the study. Horizontal EIF was significantly lower at all follow-up visits compared with baseline (p=0.001), but there were no significant differences between study eye drops (p=0.34). No significant difference in vertical EIF was observed over time (p=0.32) or between eye drops (p=0.08). Ocular symptoms significantly improved after 2 and 4 weeks of treatment compared with baseline (p<0.001), but no differences were observed between eye drops (p=0.46).

Conclusions:

All treatments were effective for reducing EIF along the horizontal meridian 48 hours after initiation of treatment, and improvements were maintained for 4 weeks. Improvements in ocular symptoms were observed with all study treatments.

News (Medical) associated with Hydroxypropyl Cellulose

20 Jul 2023

·www.prnewswire.com

REXULTI (brexpiprazole): Approved as Adjunctive Therapy to Treat Adults with MDD and Schizophrenia - Drug Insights and Market Forecasts to 2032 - Focus on 7 Major Markets

DUBLIN, July 20, 2023 /PRNewswire/ -- The "REXULTI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "This "REXULTI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REXULTI for schizophrenia in the seven major markets. A detailed picture of the REXULTI for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REXULTI for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REXULTI market forecast analysis for schizophrenia in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia. Drug Summary REXULTI (brexpiprazole) is approved as adjunctive therapy to treat adults with major depressive disorder (MDD) and schizophrenia. It is also approved to be used as adjunctive therapy to antidepressants for MDD treatment). REXULTI was discovered by Otsuka and co-developed with Lundbeck. It is co-marketed by two companies and became available to patients in the US in August 2015. The inactive ingredients consist of lactulose monohydrate, cornstarch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, and colorants of titanium dioxide, iron oxide, and ferrous ferric oxide. Also, brexpiprazole is a round tablet with six strengths ranging from 0.25 mg to 4 mg. Dosage and Administration The recommended starting dosage for REXULTI is 1 mg once daily on Days 1-4, orally with or without food. The recommended target REXULTI dosage is 2-4 mg once daily. The drug is titrated to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg. Mechanism of Action The mechanism of action of brexpiprazole in the treatment of MDD or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors and antagonist activity at serotonin 5-HT2A receptors. In-depth REXULTI Market Assessment This report provides a detailed market assessment of REXULTI for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032. REXULTI Clinical Assessment The report provides the clinical trials information of REXULTI for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates. Scope of the Report A comprehensive product overview including the REXULTI description, mechanism of action, dosage and administration, research and development activities in schizophrenia. Elaborated details on REXULTI regulatory milestones and other development activities have been provided in this report. The report also highlights the REXULTI research and development activities in schizophrenia across the United States, Europe and Japan. The report also covers the patents information with expiry timeline around REXULTI. The report contains forecasted sales of for schizophrenia till 2032. Comprehensive coverage of the late-stage emerging therapies for schizophrenia. The report also features the SWOT analysis with analyst views for REXULTI in schizophrenia. Report Highlights In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REXULTI dominance. Other emerging products for schizophrenia are expected to give tough market competition to REXULTI and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REXULTI in schizophrenia. The in-depth analysis of the forecasted sales data of REXULTI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REXULTI in schizophrenia. Key Topics Covered: 1. Report Introduction 2. REXULTI Overview in Schizophrenia 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and Efficacy 2.3. Regulatory Milestones 2.4. Other Developmental Activities 2.5. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. REXULTI Market Assessment 5.1. Market Outlook of REXULTI in Schizophrenia 5.2. 7MM Analysis 5.2.1. Market Size of REXULTI in the 7MM for Schizophrenia 5.3. Country-wise Market Analysis 5.3.1. Market Size of REXULTI in the United States for Schizophrenia 5.3.2. Market Size of REXULTI in Germany for Schizophrenia 5.3.3. Market Size of REXULTI in France for Schizophrenia 5.3.4. Market Size of REXULTI in Italy for Schizophrenia 5.3.5. Market Size of REXULTI in Spain for Schizophrenia 5.3.6. Market Size of REXULTI in the United Kingdom for Schizophrenia 5.3.7. Market Size of REXULTI in Japan for Schizophrenia 6. SWOT Analysis 7. Analysts' Views 8. Appendix For more information about this drug pipelines report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Drug ApprovalClinical Result

100 Deals associated with Hydroxypropyl Cellulose

External Link

KEGG	Wiki	ATC	Drug Bank
D04478	Hydroxypropyl Cellulose	S01	DB00840

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dry Eye Syndromes	US	Bausch & Lomb, Inc.	01 Jun 1981
Epithelial Recurrent Erosion Dystrophy	US	Bausch & Lomb, Inc.	01 Jun 1981
Hypesthesia	US	Bausch & Lomb, Inc.	01 Jun 1981
Keratitis	US	Bausch & Lomb, Inc.	01 Jun 1981
Kerato conjunctivitis sicca	US	Bausch & Lomb, Inc.	01 Jun 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2009	Not Applicable	Dry Eye Syndromes	30	Lacrisert®	rcmdtaygkn(ekogjyekye) = No significant differences uncqjxamjj (fiiuxvjqxa ) View more	Positive	01 Apr 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydroxypropyl Cellulose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation